Mr. Hugh Rogers reports
XPHYTO REPORTS MARKET AND PRODUCT DEVELOPMENTS ON PLATFORM-BASED ROTIGOTINE TRANSDERMAL PATCH FOR PARKINSON'S DISEASE
Xphyto Therapeutics Corp. has provided a market and product development report on its Rotigotine transdermal (TDS) patch. The company's Rotigotine patch is based on the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH.
Rotigotine is a non-ergoline dopamine agonist approved for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. The active pharmaceutical ingredient is not well absorbed via oral delivery and is formulated as a once-daily TDS patch to increase bioavailability and provide a slow and steady supply of the drug over the course of 24 hours. The research and development market for new formulations is competitive; however, there appears to be little success beyond the name brand product launched by the originator in 2007. According to Wissen Market Research, global sales for Rotigotine patches were approximately $518-million (U.S.) in 2021 with the market expected to surpass $766-million (U.S.) by 2030.
On May 13, 2021, Xphyto announced successful completion of a European-based human bioavailability study for its Rotigotine TDS product. The comparative study was carried out over an approximately two-week period as an open-label, randomized, crossover, two-period, two-sequence, single-dose pilot study to assess the relative bioavailability of its product compared with the name brand product. Based on the results of this study, the company is advancing the product toward a final pivotal study in Q4 2022 and, pending positive results of that study, to an application for regulatory approval.
As an interim step to evaluate optimization opportunities prior to the pivotal study, the company has completed a human cadaver skin permeation study at Vektor's EU GMP (good manufacturing practice) laboratory and manufacturing facility in Baden-Wurttemberg, Germany, to compare Rotigotine absorption between two additional derivative formulas and the name brand product. Analytical results of this study are expected to be finalized and announced in the coming weeks.
Xphyto's Rotigotine transdermal product is a single product based on Vektor's platform technology which represents a scalable opportunity for additional TDS drug development and manufacturing programs. According to Research and Markets, the global transdermal skin patch market had a value of nearly $6.5-billion (U.S.) in 2020 while Kuick Research, Pharmaceutical and Healthcare estimates the market will reach approximately $20-billion (U.S.) by 2028.
Vektor is a German narcotics manufacturer, developer and researcher located in the district of Biberach, Baden-Wurttemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sublingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global drug delivery market was valued at $1,476-billion (U.S.) in 2021 and is expected to grow to $2,047-billion (U.S.) by 2030.
Executive management of Xphyto's drug formulation business is led by Prof. Dr. Beckert, managing director of Vektor Pharma TF GmbH.
About Xphyto Therapeutics Corp.
Xphyto Therapeutics is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.